Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose?

SIMPLE SUMMARY: Relapsed/refractory classical Hodgkin’s lymphoma (cHL) accounts for 10–30% of patients. Historically, such patients were treated with salvage chemotherapy regimens followed by autologous stem cell transplantation. Introduction of novel agents such as brentuximab vedotin and immunothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Takiar, Radhika, Karimi, Yasmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318183/
https://www.ncbi.nlm.nih.gov/pubmed/35884585
http://dx.doi.org/10.3390/cancers14143526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318183/
https://www.ncbi.nlm.nih.gov/pubmed/35884585
http://dx.doi.org/10.3390/cancers14143526

Ejemplares similares